Aim and objectives: To explore the experience of pulmonary exacerbation from the perspective of adults with cystic fibrosis.
| INTRODUCTION
Cystic fibrosis (CF) is a genetic disease in which mutated proteins lead to thick, viscous secretions affecting the lungs, pancreas, liver and intestine and in which life expectancy increased to a mean survival age of 50 in the recent decades (Stephenson et al., 2015) . The main goals of CF management are to slow disease progression, especially lung damage, by preventing and treating pulmonary exacerbations, thereby providing symptom relief and improving quality of life (QOL) (Zemanick et al., 2010) . To meet these goals, patients are required to follow a complex and time-consuming medical regimen which takes about 2 hr per day in stable phases (Sawicki, Sellers, & Robinson, 2009 ). This includes chest physiotherapy and inhalation of medications. With advancing disease severity, additional management regimens are required such as blood sugar monitoring, insulin injections, tube feeding and oxygen, adding to an already complex and time-consuming regimen (Bush, Bilton, & Hodson, 2015) .
Patients living with cystic fibrosis (CF) often experience two to three pulmonary exacerbations annually (de Boer et al., 2011) . For most patients, pulmonary exacerbations mean an increase in their preexisting symptom burden due to increased sputum production, coughing, breathlessness, fever, loss of appetite and decreased exercise tolerance (Cystic Fibrosis Trust, 2009 ). Pulmonary exacerbations are generally treated with antibiotics, with a nebulised or oral antibiotic course initially being attempted. Intravenous antibiotics might alternatively be indicated, with home treatment being an additional treatment modality offered to patients (Cystic Fibrosis Trust, 2009 ).
Thus, patients face an increase in both symptom burden and treatment-related burden, likely having a negative effect on fatigue and the person's sense of mastery over the illness and symptoms (Balaguer & Gonzalez de Dios, 2012) . Thus, suboptimal self-management in relation to CF therapy may ensue, for example, nonadherence to respiratory physiotherapy, which may in turn affect clinical outcomes such as lung function (Esmond, Butler, & McCormack, 2006) . A recent synthesis of qualitative studies provided a first insight and indicated that patients experiencing a pulmonary exacerbation often described a sense of loss or fear of loss, including decreased physical functioning and associated distress (Schmid-Mohler, Yorke, Spirig, Benden, & Caress, 2018) . This review highlighted a current lack of insight regarding what exacerbations indicate for patients and how the experience impacts patients' self-management. Understanding patients' experience of a pulmonary exacerbation is essential in order to develop interventions that support self-management and for the development of patient-reported outcome measures to enable evaluation of the efficacy of the interventions.
The aim of this study was to explore the experience of adults with CF during a pulmonary exacerbation over time. Data collection and interpretation of findings were guided by Symptom Management Theory (Dodd et al., 2001; Humphreys et al., 2014) , which describes several phases of symptom experience and self-management.
| METHODS

| Design
This qualitative study was undertaken within a convergent mixedmethod research project (Creswell, 2015; Creswell & Plano Clark, 2011) , using a longitudinal design in a subsample.
The study was approved by the Ethics Committee of Zurich Switzerland and performed in line with the Declaration of Helsinki.
All patients completed informed consent forms. Two patients were involved in designing the study (per INVOLVE guidance, 2012) and assessed the study's relevance as high.
| Theoretical framework guiding this study
Data collection and interpretation of findings were guided by Symptom Management Theory (Dodd et al., 2001; Humphreys et al., 2014) which describes three phases of symptom management: First, patients experience symptoms by perceiving, evaluating and responding to them. Second, they manage the symptoms. Third, their symptom management results in outcomes such as emotional or physical functioning. The three steps interact simultaneously and continue until symptoms resolve themselves or stabilise. The three concepts are influenced by contextual variables, that is, personal, What does this paper contribute to the wider global clinical community?
• These findings provide an understanding that patients have goals, conscious or subconscious, that guide their self-management decisions in acute phases such as pulmonary exacerbations. Elaborating on and balancing these goals in a shared decision-making process between healthcare professionals and patients may lower patient distress and improve self-care.
• This study provides the basis for the development of future patient-reported outcome measures and interventions.
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| 191 environmental, health and/or illness-related factors. The theory guided the development of the interview guide and the indexing stage of analysis.
| Setting and Sample
The study was conducted between April 2015-July 2016 at a large university hospital in Switzerland.
| Inclusion and exclusion criteria
Two different samples were recruited (Cohorts A and B). Inclusion criteria for both cohorts were as follows: a confirmed diagnosis of CF, 18 years of age or older and no solid organ transplant. Additional inclusion criterion for Cohort A was having experienced at least one pulmonary exacerbation in the previous year and for Cohort B, currently experiencing an acute pulmonary exacerbation.
Acute pulmonary exacerbation was defined according to recognised criteria (Fuchs et al., 1994) as requiring oral or intravenous antibiotic treatment. The exclusion criterion for both cohorts was inability to speak or understand German.
For Cohort A only, purposive sampling was applied, guided by a 5-year survivorship model (Liou et al., 2001) . Sampling criteria were age, gender, FEV 1 (forced expiratory volume in 1-s) in stable phases, number of pulmonary exacerbations in the past year requiring antibiotic treatment and BMI.
| Data collection
Patients were informed about the study by their CF team. If interested, patients were contacted by the first author, who had not been in prior contact with any of the patients. Further information was provided to the patients, and their consent was sought. Four patients declined to participate for reasons that included time shortage (n = 2), feeling uncomfortable with audio recording (n = 1) or unwillingness to speak about this topic (n = 1).
Cohort A patients were interviewed once by the first author.
Cohort B patients were interviewed by the first author in the first week and second week after the commencement of antibiotic treatment and in the first or second week after antibiotic treatment completion. The first and second interviews were mainly over the telephone and focused on current symptom experience and management. The third interview was always conducted in person-1-2 weeks after termination of the antibiotics. The location for the interview was chosen by patients (their home, workplace or office of the researcher). The researcher took field notes directly after the interview (see Table 1 for the interview guideline). Clinical data were retrieved from medical files, with patient consent. Data collection was concluded after no new substantial information could be obtained.
| Data analysis
The qualitative interviews were audio-recorded, transcribed verbatim and analysed according to Framework Analysis which is a method widely used in health service research to analyse and summarise data under a predefined index (Ritchie, Spencer, & O'Connor, 2003) . We used a combination of deductive and inductive analysis, guided by Symptom Management Theory and the research question (Gale, Heath, Cameron, Rashid, & Redwood, 2013) . Data were entered into the framework matrix, using QSR NVivo 10, and labelled using the predefined concepts according to the elements of the Symptom Management Theory (perception, evaluation, response, management strategies, outcomes and influencing factors) and the research questions (meaning, distress and evolvement over time).
The data in the concepts were analysed inductively to identify subthemes, and the final index, with concepts and subthemes, was defined and presented in a final theoretical framework (Figure 1 ).
Data from both cohorts were combined by indexing data with timeframes (i.e., before, during or after antibiotic treatment, deterioration or improvement of symptoms, number of days or weeks) and summarising the data which referred to the same timeframe.
To ensure rigour, German-language transcripts were read by the third author, who is a native German speaker. Each transcript was summarised in English and read by the second and last authors. The authors discussed the framework index at monthly sessions during the analysis process, and two patients reviewed the findings and reported that they each found "their exacerbation story" within the summary.
| RESULTS
| Characteristics of the Sample
Eighteen patients (7 female; aged 19-55, forced expiratory volume in 1 s (FEV 1 ) 23%-105%) participated (Table 2 ). Eleven patients (Cohort A) were interviewed once, and seven patients (Cohort B) were interviewed three times. One patient in Cohort B was interviewed only twice due to receiving a lung transplant after the second interview. In Cohort A, interviews lasted 63-94 min. In Cohort B, the first and second interviews lasted 15-60 min, and the third interview 48-96 min.
T A B L E 1 Interview guideline
Interview questions
• What does having an exacerbation mean?
• When experiencing an exacerbation: what is important for you?
• How did you realise that you have an infection? How did you react? • Recall a really distressing/easy day: Tell me about this distressing/ easy day.
• What was special on that day?
• What was distressing for you?
• Which actions did you take to lower the distress (of the symptoms)?
• How must the symptoms change for you to say "now my health is better"? On which day is that normally the case?
| The pulmonary exacerbation trajectory
Themes and subthemes from the framework index are written in italics or in brackets and are presented in Figure 1 . Patients experienced an exacerbation as a trajectory from noting a change, waiting until the antibiotics helped, returning to normality until establishing new normality.
In the first phase, patients "noted a change" in their usual condition and had difficulty accepting that keeping up normality was not possible and treatment was needed, which might last from some hours to several weeks. This second phase "waiting until the antibiotics help" included the time when patients experienced the peak of symptom burden as well as the point of change, typically between Days three-five, when the antibiotics take effect. Some patients with mild CF lung disease (FEV 1 > 60%) reported that during some "mild" exacerbations they did not experience this peak of symptoms and were able to continue working. Their experience was identical to that reported in the next (third) phase. The third phase "returning to normality" was the time after the point of change. In this phase, the symptoms improved steadily and patients took up normal life again, but treatment burden remained high. It lasted until the end of treatment, normally after 2 weeks. The fourth phase "establishing 
| Noting a change
Patients described their "normality" as their daily life with the usual symptoms and treatment which they perceived as "belonging" to them. Only one patient did not have any symptoms or therapy in stable phases. All others experienced at least one CFspecific symptom (e.g., coughing) in stable phases, requiring at least one treatment, such as inhalation. Nonetheless, they perceived themselves as "normal" and some even "healthy" in stable Swiss and other (n) 1
Marital status
Living situation
Living alone 5
Living with parents and siblings 5
Living with partner or friends 8
Education (highest completed or in progress)
In training (n) 1
Higher apprenticeship/college (n) 4 University (n) 4
Working/studying Not working or studying 0% (n) 4
Part-time, with lower workload 10%-50% (n) 3
Part-time, with higher workload 60%-90% (n) 2
Full-time 100% (n) 9
And when I come out of the pharmacy with all of these bags full of material for the intravenous treat- Home administration was also preferred if the patient's living situation (purpose in life) conflicted with a hospital stay because they had care responsibilities towards children or pets or felt some obligation to be present at work (working situation). Some patients believed hospital treatment to be more effective than home intravenous treatment.
| Waiting until the antibiotics help
Patients generally experienced a peak of symptom burden at the start of treatment and, in the first day of antibiotic treatment, often accompanied by a lack of control over bodily symptoms, particularly coughing, and an overwhelming lack of energy. These were so strong for some patients that they felt that CF took control of the body and that the body dominated life (domination of CF):
You're kind of at the mercy of your body and you just have to wait until your body responds to the treatment. In that moment I have to admit that my body is stronger than my own will. I can't fight against it, just have to accept it.
(ID 67)
Symptoms and treatment consumed a substantial part of the patients' energy which had already been depleted. Coughing in particular was reported to take a lot of energy. Often symptoms such as nighttime coughing affected sleep. In addition, decreased muscle strength and weight loss added to the lack of energy, leading to loss of appetite.
The treatment consumed energy as well: Airway clearance therapy triggered energy-depleting coughing, and some patients reported fatigue as a side effect of the intravenous antibiotics (consumption of energy).
Just after the infusion, I've felt so weak that I had to immediately get into bed and rest for at least an hour.
In the morning I've inhaled, coughed up, inhaled. I need at least an entire hour for everything. Then I am totally exhausted. Also after a coughing attack, I completely collapse, so that I'm not able to do anything for a while. During the first phase of the pulmonary exacerbation, getting better and regaining control of symptoms were the predominant outcome goals for patients.
| Returning to normality
After patients experienced a significant improvement in symptoms, normally three to five days after start of the antibiotic treatment, they attempted to return to normality. They had more energy for doing chores or undertaking things. Patients reported that the first sense of normality came when they felt a desire to get things done or to do chores at home again:
Normality returns … when I suddenly feel like doing things again. Then I know: yes, then it's good. When I get restless and no longer want to stay home, or I do this or that, or do some more work at home. I got back to normal from the day that I was allowed to go home (to continue with home intravenous therapies)…. I was really happy on that day, as if it had all never happened. As of that day I've also started to Administering antibiotics at home was one strategy often applied to combine non-illness-specific daily demands with illness-specific demands. For some, this resulted in excessive demands, especially if combining full-time work with an intravenous regimen requiring administration four times a day (treatment modality) and a not fully functioning intravenous access.
| Establishing (new) normality
Patients reported that with finishing the antibiotic treatment they had a feeling of "being normal again":
You take the venous catheter out and you're OK and then normal life starts again …It's a bit like when you run a computer at full speed and then have to turn off the power switch and you have to start it again and do the system check until the black screen comes up that shows strange stuff. The phase is kind of like that.
(ID 10)
Full normality was established after some weeks or even 2-3 months after having achieved the same or similar level of physical performance.
For some patients, "new" normality described living with a slightly reduced level of physical performance. Some patients reported that increased symptoms, for example, breathlessness and lack of energy, made keeping up with others impossible and also led to separation. COPD has grown, indicating that symptoms related to posttraumatic stress disorder increase as the patient's exacerbation progresses (Chung, Jones, Harding, & Campbell, 2016; Teixeira et al., 2015) . This connection of loss of control and threat to the pulmonary exacerbation experience has been reported in children with asthma as well (Trollvik, Nordbach, Silén, & Ringsberg, 2011) . This novel finding is important and merits further attention from researchers, given that pulmonary exacerbations subjectively experienced as "severe" have been found to have an impact on longterm depressive symptomatology in CF (Olveira et al., 2016) . This is particularly so in CF, as a decline in lung function predicts a decline in physical, social and emotional functioning (Abbott, Hurley, Morton, & Conway, 2013) . Our findings further suggest that self-management interventions during pulmonary exacerbations should aim to increase the patient's feeling of control and decrease feelings of threat.
The strength of this study was the longitudinal exploration of the pulmonary exacerbation experience in a subsample which made a description of the phenomenon over time possible. A limitation of this study is that it included only Swiss patients from a single centre. There was consequently little cultural diversity in this study's sample. It is likely that exacerbation and symptom experience are influenced by cultural values and the healthcare system (Bacon et al., 2009 , Dodd et al., 2001 ; therefore, pulmonary exacerbation experience may be different in other cultures.
| CONCLUSION
These findings highlight that health professionals must acknowledge emotional distress as a key driver for self-management decisions and consider the different sources of emotional distress within a shared decision-making process.
| RELEVANCE FOR PRACTICE
These findings provide an understanding for the patients' experience of pulmonary exacerbations. They highlight that an assessment of patients' distress and goal are a prerequisite for the development of patient-centred and patient-accepted care plans during pulmonary exacerbations. Nurses play a key role, as they are involved in the management of CF exacerbations and provide self-management education and psychosocial support during these episodes (Conway et al., 2014; Kerem, Conway, Elborn, Heijerman, & Consensus, 2005) .
The nurses' awareness and acknowledgement of patients' experience may therefore substantially contribute to improved communication and interaction between patients and the CF team during pulmonary exacerbations.
Furthermore, these findings will inform and provide invaluable guidance for future research to develop interventions and patientreported outcome measures to measure illness-related emotional distress.
